IGLV2-8

Across TCGA pan-cancer cohorts, IGLV2-8 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IGLV2-8’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where IGLV2-8 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLV2-8 is over-expressed in tumor, although a few such as COAD and LIHC show the opposite, repressed pattern.

COAD, LUAD, and KIRC are the cancer types where IGLV2-8 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV2-8 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	−4.848	<.001	12	view →
LUAD	Female	All	+1.783	<.001	7	view →
KIRC	Male	All	+1.920	<.001	6	view →
LIHC	Male	All	−2.287	<.001	4	view →
BRCA	Female	II,III,IV	−1.318	<.001	4	view →
READ	All	All	−3.852	.001	3	view →
KICH	All	II,III,IV	−1.333	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IGLV2-8–COAD

Open the COAD breakdown →